138 results about "Ethanolamine synthesis" patented technology

The invention relates to the field of traditional Chinese medicine effective component new dosage form pharmaceutical preparations, and discloses an M2 type macrophage membrane coated ROS responsive bionic nano drug delivery system, preparation and application. Mesoporous silica is used as a core to load a traditional Chinese medicine effective component, namely tripterine, and lipid components, namely PEGylated distearoyl phosphatidyl ethanolamine (DSPE-PEG), dioleoyl lecithin (DOPC), cholesterol and the like, are used as raw materials to prepare a ROS-responsive lipid coating, so that ROS-responsive tripterine mesoporous silica is formed. And then realizing bionic fusion with the M2 type macrophage membrane on the outer layer through an ultrasonic coating technology to prepare the M2 type macrophage membrane coated ROS responsive bionic mesoporous silica nano drug delivery system. The invention can realize targeted therapy of rheumatoid arthritis, and has the advantages of biological safety and the like.

The metabolic marker can be used for early diagnosis of heart failure, has the advantages of high sensitivity, rapidness, convenience and accurate and reliable result, provides a basis for clinical decision, provides a certain basis for subsequent fundamental research and clinical research, and has potential application and research values. The metabolic marker comprises one or more of 1-(4-nitrophenyl) piperidine, sphingolipid d19: 3 / 23: 0, phosphatidyl ethanolamine 16: 1e / 22: 5, phosphatidyl ethanolamine 16: 1e / 22: 6, sphingolipid d14: 0 / 22: 1, 3-phosphoglyceric acid, phosphatidylcholine 15: 0 / 20: 4, phosphatidylcholine o-16: 1 / 18: 0, phosphatidylcholine 14: 0e / 20: 1, phosphatidylcholine 17: 0 / 18: 5, betaine, phosphatidylcholine 15: 0 / 18: 2 and phosphatidylcholine 18: 5e / 20: 4.

The invention discloses a lipid composition for preparing extracellular vesicles, which is prepared from the following lipid substances in percentage by mass: 2 to 18 percent of phosphatidylcholine, 2 to 14 percent of phosphatidylethanolamine, 7 to 27 percent of sphingomyelin, 0.5 to 7 percent of ceramide, 1.5 to 2.5 percent of phosphatidylinositol, 30 to 70 percent of cholesterol and 5 to 8 percent of phosphatidylserine, the fatty acid carbon number of the lipid substance satisfies the following conditions: the fatty acid carbon number of phosphatidylcholine is 16-20, the fatty acid carbon number of phosphatidyl ethanolamine is 16-18, the fatty acid carbon number of sphingomyelin is 16-24, the fatty acid carbon number of ceramide is 16-24, the fatty acid carbon number of phosphatidylinositol is 16-20, the fatty acid carbon number of phosphatidylserine is 18-24, and the molar ratio of cholesterol to sphingomyelin is 4-7. The extracellular vesicles are prepared from the lipid composition and used for biomarkers or drug carriers, and efficient oral drug delivery is achieved.

The invention discloses an emulsifier for preparing a Pickering emulsion, the Pickering emulsion as well as a preparation method and application of the Pickering emulsion. The emulsifier of the Pickering emulsion is obtained by dissolving distearoyl phosphatidylcholine, cholesterol and distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000 in ethanol, carrying out rotary evaporation to remove ethanol, then adding an antigen aqueous solution containing an antigen, continuing rotary evaporation to obtain liposome nanoparticles, heating the liposome nanoparticles with mannose in a water bath, and carrying out freeze drying. The Pickering emulsion is obtained by dispersing an emulsifier in water as a water phase, taking squalene as an oil phase, mixing the water phase and the oil phase, and homogenizing. The Pickering emulsion disclosed by the invention is prepared by taking antigen presenting cell targeted liposome nanoparticles as a raw material; and the antigen has excellent ion concentration characteristic, pH stability, temperature stability and storage stability, and can protect the integrity of the antigen.

The invention discloses injectable oxygen-carrying and medicine-carrying microbubble composite hydrogel with immunoregulation performance and a preparation method of the injectable oxygen-carrying and medicine-carrying microbubble composite hydrogel, and belongs to the field of tissue damage treatment. The preparation method comprises the following steps: carrying out a reaction on hyaluronic acid HA and dipalmitoyl phosphatidyl ethanolamine DPPE to construct a microbubble monomer DPPE-HA; the preparation method comprises the following steps: fully dissolving DPPC (dipalmitoyl phosphatidylcholine), DPPE-HA (dipalmitoyl phosphatidylcholine) and a therapeutic drug into a solvent, introducing oxygen and carrying out mechanical oscillation to obtain oxygen-carrying and drug-carrying microbubbles; the oxygen-carrying and drug-carrying microbubbles are uniformly doped into a vinyl modified natural polymer solution, and the oxygen-carrying and drug-carrying microbubble composite hydrogel is formed through photo-crosslinking. The obtained injectable microbubble hydrogel can be used for treatment of different tissue injuries, including wound repair and burn treatment, osteochondral injury repair, cardiovascular disease treatment and nerve injury repair, in addition, the injectable microbubble hydrogel can also be applied to the fields of cosmetic plastic surgery, skin regeneration and the like, and has a wide clinical application prospect.

The invention discloses dipeptide hydrogel and application thereof as a cell culture medium, and belongs to the field of material science. According to the invention, the dipeptide hydrogel is designed and assembled, and the dipeptide hydrogel is prepared by the following steps: carrying out self-assembly on phenylalanine dipeptide modified by 9-fluorenyl methoxy carbonyl protecting group (Fmoc), and then adding tetracarboxyl phenyl porphyrin (TCPP) and distearoyl phosphatidyl ethanolamine (DSPE) for co-assembly. When the dipeptide hydrogel prepared by the invention is applied as a cell culture medium, the proliferation activity of cultured cells can be improved, so that the growth speed and density of the cells are improved, and the dipeptide hydrogel has good biological safety. The possibility is provided for promoting the high-level development of the cell culture field.

The invention belongs to the technical field of pharmaceutical preparations. The invention discloses a nano preparation for inhibiting tumor metastasis, a preparation method and application. The nano preparation for inhibiting tumor metastasis comprises liposome spheres and nano spheres. The liposome sphere provided by the invention comprises an inner-layer core structure and a shell wrapping the outer layer of the inner-layer core structure, wherein the inner-layer core structure comprises lecithin, dioleoyl phosphatidyl ethanolamine, cholesterol succinic acid monoester, cholesterol, imidazolyl-cholesterol and DSPE-PEG2000-CS; the core structure of the inner layer is loaded with aspirin and DNaseI; the housing includes platelets. The nano preparation for inhibiting tumor metastasis can dissolve NET, inhibit the platelet function and disintegrate tumor cell-platelet-NET aggregate, and the nanosphere for inhibiting the far-end metastasis of tumors can deeply permeate into the tumors to play a role in killing the tumors.

The invention belongs to the field of substance content detection, and discloses a method for determining the content of soybean phosphatidylcholine or phosphatidylethanolamine in a soft capsule, which comprises the following steps: (1) preparing a soybean phosphatidylcholine or phosphatidylethanolamine standard solution; (2) preparing a to-be-detected sample solution; (3) performing high performance liquid chromatography analysis; (4) drawing a standard curve; and (5) calculating the content of soybean phosphatidylcholine or phosphatidyl ethanolamine. The method has the advantages of high response value, short retention time and stable base line, and is not interfered by other components in the soft capsule; the method has the advantages of simple operation, high precision and good repeatability, the recovery rate meets the analysis requirement, and the method can efficiently, quickly and accurately detect the content of two components, namely soybean phosphatidylcholine and phosphatidyl ethanolamine, of soybean phospholipid in the soft capsule content.

The invention relates to the technical field of liposome preparation, and particularly discloses a nano liposome and a preparation method thereof.The method comprises the steps that distearoyl phosphatidyl ethanolamine, cholesterol, hydroxyl-terminated polyethylene glycol and mPEG-Hyd-PEG-SH are dissolved in a mixed solvent, and a lipid film is formed through rotary evaporation; hydrating with a PBS (Phosphate Buffer Solution) containing ammonium sulfate, and carrying out ultrasonic treatment to obtain primary emulsion; a doxorubicin solution is added for incubation, and drug loading is completed; the CD44 antibody and the drug-loaded liposome are coupled in a catalytic system, and are homogenized by a spiral microreactor. The problems of high immunogenicity, insufficient targeting, non-uniform particle size, uncontrollable drug release and complex preparation process of the existing PEG nano-liposome are solved, and the PEG nano-liposome has the advantages of low immunogenicity, high targeting, uniform and stable particle size, drug response release and easiness in large-scale production.

The invention provides a multifunctional cisplatin liposome as well as a preparation method and application thereof. The liposome is prepared from epigallocatechin gallate, cis-platinum, zinc peroxide nanoparticles, a distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000 long-acting fragment, a distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000-oestrone targeting fragment, lecithin and cholesterol, and the particle size of the liposome is 80 to 130 nm. According to the multifunctional liposome disclosed by the invention, the zinc peroxide nanoparticles are introduced, so that the function of slowly releasing oxygen in a tumor microenvironment can be realized, and oxygen deficit is reversed; through targeting fragment modification, an active targeting effect can be realized by combining with an estrogen receptor highly expressed on the surface of a breast cancer cell; the epigallocatechin gallate and cis-platinum are co-loaded, so that the sensitivity of chemotherapeutic drugs can be improved, the toxic and side effects of the chemotherapeutic drugs are reduced, a good breast cancer resisting effect is achieved, and the tumor volume is remarkably reduced.

The application discloses a liposome of a FOXO1 inhibitor AS1842856 and a preparation method and application thereof. The liposome comprises the following raw materials: phospholipid, cholesterol, phospholipid PEG derivative and AS1842856; wherein the proportion of the phospholipid, the cholesterol and the phospholipid PEG derivative (for example, distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000 (DSPE-PEG2000)) is preferably in the range of 10:0.2-2:0.5-5 (w / w); wherein the AS1842856 is wrapped in the liposome. The AS1842856 liposome of the application has excellent physical and chemical properties and has a wide application prospect in the field of fibrosis disease treatment.

The invention provides application of phosphatidyl ethanolamine in improving resistance of morchella to white mold. Experimental verification shows that exogenous addition of the phosphatidyl ethanolamine can enhance the resistance of the morchella to pseudomonas longispora, so that the resistance of the morchella to the white mold is improved, the development of the white mold is inhibited, the growth of a morchella sporocarp is promoted, and the application possibly has huge potential in the aspect of development of morchella white mold prevention and treatment products.

The invention discloses an iron MOF (Metal Organic Framework) nanoparticle and a preparation method thereof. Specifically, the preparation method comprises the following steps: by taking iron MOF, GOX, egg yolk lecithin, cholesterol, distearoyl phosphatidyl ethanolamine (DSPE), Ce6 and HCPT as reaction raw materials, preparing the Ce6-coated HGMOF nano-particles through a thin lipid membrane hydration and sequential extrusion method. The iron MOF nanoparticles can relieve hypoxia and have photodynamic and ferroptosis treatment effects at the same time.

The invention discloses a W / O / W type nano-emulsion loaded with cocaine esterase as well as a preparation method and application of the W / O / W type nano-emulsion. The nano-emulsion is prepared from cocaine esterase, a phosphate buffer solution, soybean phospholipid, vitamin E polyethylene glycol succinate, distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000 and medium chain triglyceride. The preparation method comprises the following steps: preparing the inner water phase; preparing an oil phase; slowly injecting the internal water phase into the oil phase under shearing to obtain W / O type primary emulsion; slowly adding the primary emulsion into the external water phase under shearing, and performing high-speed shearing to obtain a secondary emulsion; and performing high-pressure homogenization on the secondary emulsion to obtain the final W / O / W type nano-emulsion. The cocaine esterase is combined with the nano-emulsion for the first time, and the nano-emulsion prepared by the method has the effects of improving the temperature stability of the cocaine esterase and prolonging the in-vivo half-life period, and can be applied to rescue or prevention of cocaine acute poisoning.

The invention discloses a nanoscale water plugging agent which comprises the following components in parts by weight: 5-8 parts of white oil; 30 to 40 parts of a comonomer; 10 to 14 parts of a composite emulsifier; 20 to 26 parts of a composite monomer; 20 to 26 parts of deionized water; 0.2 to 0.3 part of a cross-linking agent; 2 to 3 parts of rhamnolipid; 2 to 3 parts of phosphatidyl ethanolamine; and 0.02 to 0.03 part of an initiator. The water plugging agent can smoothly enter the deep part of a stratum along with injected water, and plugging of a stratum pore throat is realized after the water swelling. The invention also discloses a preparation method of the nanoscale water shutoff agent.

The invention discloses a biomarker for distinguishing prostatic cancer and benign prostatic hyperplasia and application thereof, and particularly provides phosphatidyl ethanolamine (20: 0 / 15: 0) as a biomarker for screening prostatic cancer, the phosphatidyl ethanolamine (20: 0 / 15: 0) has higher specificity and better diagnostic efficiency than TPSA, can reduce unnecessary prostatic biopsy puncture, and can be used for screening prostatic cancer. The pain of a patient is relieved, and missed diagnosis of conventional puncture is reduced.

The invention provides a lipidosome. The lipidosome is prepared from phospholipid, cholesterol and distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000-glutamine. The lipidosome is prepared from the phospholipid, the cholesterol and the distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000-glutamine. The invention further provides a corresponding lipidosome nano-drug delivery system, a preparation method thereof and application of the lipidosome nano-drug delivery system in treatment of cervical cancer. By utilizing the difference between cervical cancer cells and normal cells, the glutamine is modified on the surface of the liposome, so that the accurate targeting of the drug on cervical cancer is realized. The lipidosome nano-drug delivery system has the advantages of good biocompatibility, low immunogenicity, high drug loading capacity, degradability and good stability, the circulation time in blood can be prolonged, and the cervical cancer treatment effect is improved at the same time.

The invention belongs to the technical field of spectral analysis and detection, and particularly relates to a preparation method and application of a surface-enhanced Raman flexible substrate. The surface-enhanced Raman flexible substrate comprises a substrate, metal composite nano-particles with core-shell structures are uniformly distributed on the substrate, and the metal composite nano-particles are formed by coating metal nano-particles with stearoyl phosphatidyl ethanolamine-polyethylene glycol-sulfydryl. The preparation method of the flexible substrate comprises the following steps: preparing metal nanoparticles; dSPE-PEG-S-metal composite nano particles are prepared, and the DSPE-PEG-S-metal composite And preparing the DSPE-PEG-S-metal composite nano particle substrate. The single-layer metal composite nanoparticles which are uniformly and stably dispersed are arranged on the Raman flexible substrate, so that the phenomena of non-uniformity, easiness in agglomeration and the like of the substrate are effectively solved, the stability and the reliability of SERS signals are improved, and the Raman flexible substrate can be applied to exosome detection and analysis.

The invention relates to the technical field of adhesives, in particular to a modified phenolic resin adhesive and a preparation method thereof. The problems of excessive formaldehyde emission, long curing time, poor wear resistance, low bonding strength and poorer toughness of a phenolic resin adhesive are solved. By controlling the use amount of urea, urea reacts with formaldehyde to generate urea-formaldehyde resin, so that the content of free formaldehyde in the adhesive is reduced; the curing speed of the resin is increased by changing the dosage of the basic catalyst and the type and dosage of the curing agent; the chemical structure of the phenolic resin adhesive is changed by adding the cashew nut shell oil, and the crosslinking density and hardness of the phenolic resin adhesive are increased, so that the wear resistance of the adhesive is improved; by changing the dosage of formaldehyde and the type and dosage of the silane coupling agent, the binding force between the adhesive and a base material is enhanced, and the bonding strength is improved; vanadium pentoxide is modified by dioleoyl phosphatidyl ethanolamine, and the use amount of the modified vanadium pentoxide is changed, so that the toughness of the adhesive is improved.

The invention discloses a phospholipid compound for inhibiting beta-amyloid protein aggregation, and the chemical structural formula of the phospholipid compound is as follows: # imgabs0 #, and n is an integer greater than 2. Dioleoyl phosphatidyl ethanolamine molecules are modified by utilizing maleimide alkyl carboxylic acid and glutathione, so that the interaction between a phospholipid compound and amyloid protein can be effectively regulated and controlled, and the aggregation of the amyloid protein is delayed and even inhibited; the preparation method is simple, the reaction energy consumption is low, and the obtained phospholipid compound has good biocompatibility and is suitable for popularization and application.

The application relates to the field of medicine, in particular to a ROS (reactive oxygen species)-responsive liposome containing kaempferol and a preparation method and application thereof, to solve the problems of poor kaempferol efficacy and how to reduce the toxicity of PFOB in the prior art, realize stable kaempferol drug release, and improve the bioavailability. The liposome is a ROS-responsive liposome containing kaempferol, the liposome is a DTP liposome, the DTP liposome is a double-layered inner and outer layer with distearoyl phosphatidyl ethanolamine-polyethylene glycol as the outer shell of the liposome, a ketone thioacetal bond is located between the outer shells of the liposome, the drug loaded in the DTP liposome is a PEG-PFOB-PEG-kaempferol combination, namely a DTP@PPPK liposome, and the DTP@PPPK liposome can fully exert the efficacy and improve the safety.

The invention relates to an exosome-like nano-vesicle for gene delivery and a preparation method thereof, the exosome-like nano-vesicle comprises a lipid phase and an inner water phase entrapped in the lipid phase, the lipid phase is prepared from cholesterol, phosphatidyl ethanolamine, phosphatidylserine, phosphatidylcholine and sphingomyelin; the inner water phase comprises nucleic acid drugs. The raw material components of the lipid phase are set, the use of cationic lipid and ionizable lipid is avoided, so that the anionic lipid vesicles simulating exosome lipid components can be prepared, the lipid phase entraps the internal water phase containing nucleic acid drugs, and the lipid vesicles have the characteristics of good stability, low toxicity and high transfection efficiency; the exosome has the advantages of limited immunogenicity, high delivery efficiency and enhancement of stability in the in-vivo circulation process of the natural exosome, the preparation process and the final quality are controllable, and commercialized production and clinical transformation are easier to realize.

The invention discloses a pH-sensitive bionic drug lipid vesicle as well as a preparation method and application thereof. The bionic drug lipid vesicle is a drug-loaded lipid vesicle formed by mixing a cell membrane vesicle and drug-loaded phospholipid and then carrying out self-assembly, the drug-loaded phospholipid is obtained by connecting a drug and distearoyl phosphatidyl ethanolamine-polyethylene glycol (DSPE-PEG) through a pH-sensitive connecting agent cis-aconitic anhydride. The bionic drug lipid vesicle prepared by the invention has excellent pH response capability, can accurately respond to the pH value change of a tumor microenvironment, and realizes tumor targeted release of the drug. The bionic drug lipid vesicle is prepared by adopting a method of ultrasonic self-assembly after physical mixing, the operation is simple, convenient and feasible, and the requirement on process conditions is relatively low.

The invention discloses a phototherapy nano-drug with mitochondrial / STAT3 protein double-site targeting. The phototherapy nano-drug is ATO / CR nano-particles formed by self-assembling a compound CR and atorvaquone under the action of distearoyl phosphatidyl ethanolamine-polyethylene glycol; the structure of the compound CR is shown as a formula I in the specification. The invention discloses an application of the phototherapy nano-drug with mitochondrial / STAT3 protein double-site targeting in preparation of drugs for treating tumors. The phototherapy nano-drug can target mitochondria and STAT3 protein in tumor cells through ATO, and can also passively target tumor sites through the high-permeability long-retention effect of nano-particles, so that more nano-therapeutic agents are enriched around tumors, and the curative effect is improved. The phototherapy nano-drug provided by the invention has good photothermal performance, can effectively enhance the PTT effect of gastric cancer, and exerts the tumor synergistic treatment ability by promoting cell apoptosis, inhibiting angiogenesis and hindering the cell cycle.

The invention relates to chlorotoxin-melittin nanoparticles as well as a preparation method and application thereof. The method comprises the following steps: weighing chlorotoxin, dissolving the chlorotoxin in a PBS buffer solution, adding 2-imino sulfane hydrochloride, fully mixing, and incubating at room temperature to form a CTX-SH solution; the preparation method comprises the following steps: weighing dimyristoyl phosphatidylcholine, adding a trichloromethane solution, uniformly mixing, then adding a cholesterol oleate solution and a phosphatidyl ethanolamine-polyethylene glycol 2000-maleimide solution, and sufficiently and uniformly mixing; drying the solution, resuspending with a PBS (Phosphate Buffer Solution), and fully dissolving by ultrasonic; adding a thiolated CTX-SH solution into the solution, incubating for 1-3 days, and carrying out ultrafiltration purification to form a CTX-NP nanoparticle solution; preparing a melittin solution, dropwise adding the melittin solution into the CTX-NP nanoparticle solution, incubating for 10-24 hours, and performing ultrafiltration purification. The invention has the advantages of targeting brain glioma, inhibiting the growth of in-situ brain glioma and improving the immunosuppressive microenvironment of brain glioma.

The application belongs to the technical field of pharmaceutical preparations, and discloses a nano-liposome with synergistic effect of double adjuvants and a preparation method and application thereof.The preparation method of the nano-liposome with synergistic effect of double adjuvants comprises the following steps: (1) mixing manganese chloride solution, cationic liposome, distearoyl phosphatidylcholine, distearoyl phosphatidyl ethanolamine-polyethylene glycol, cholesterol and a solvent to react, and evaporating to obtain a lipid film; (2) mixing the lipid film, human unmethylated oligodeoxynucleotide and water to heat, and filtering to obtain the nano-liposome with synergistic effect of double adjuvants.The obtained nano-liposome with synergistic effect of double adjuvants has excellent sustained release property.The obtained nano-liposome with synergistic effect of double adjuvants has stable physicochemical properties after being prepared into a nano-liposome vaccine adjuvant, and is convenient to store and transport.

The invention provides an anti-neuroinflammation medicine as well as a preparation method and application thereof. The anti-neuroinflammation medicine comprises an active component and lipidosome, the active component is an inhibitor 4-aminobenzoyl hydrazine of myeloperoxidase; the liposome is prepared from phospholipid, cholesterol and distearoyl phosphatidyl ethanolamine-thioketal-polyethylene glycol; the method comprises the following steps: weighing lipidosome and 4-aminobenzoyl hydrazine, dissolving, and carrying out rotary evaporation to obtain a lipid membrane; adding a phosphate buffer solution into the lipid membrane, stirring in a water bath, performing ultrasonic treatment, filtering, centrifuging and purifying to obtain the medicine, according to the active oxygen response-based liposome delivery system disclosed by the invention, 4-aminobenzoyl hydrazine is encapsulated in liposome to form a drug, and after the drug enters a brain inflammation microenvironment area of the Alzheimer's disease, the active oxygen can break a thioketal bond, so that local release of 4-aminobenzoyl hydrazine is triggered, targeted inhibition of myeloperoxidase is realized, and the drug delivery effect is improved. The oxidative stress level is reduced, the neuroinflammation is relieved, and the cognitive impairment is effectively improved.

The invention discloses a preparation method of hyaluronidase modified quercetin lipidosome, and relates to the technical field of natural plant preparations, and the preparation method comprises the following steps: step 1, weighing distearoyl phosphatidylacetamide-polyethylene glycol 2000-succinimide, dissolving in dimethylformamide, adding hyaluronidase, dialyzing in pure water, filtering, and drying to obtain a quercetin liposome solution; and carrying out freeze drying to obtain the DSPE-PEG2000-HAase. 2, adding quercetin, lecithin and cholesterol into a solvent, mixing, and carrying out reduced pressure rotary evaporation to obtain an oil phase; step 3, preparing a PBS (Phosphate Buffer Solution), adding distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000-hyaluronidase, and uniformly mixing, so as to obtain a PBS-DSPE-PEG2000-HAase solution, namely a water phase; and 4, adding the water phase into the oil phase, heating in a water bath, and emulsifying to obtain the hyaluronidase modified quercetin liposome. The hyaluronidase modified quercetin liposome obtained by the invention is small in particle size, uniform in distribution and high in encapsulation efficiency, is beneficial to intravenous injection, effectively plays an anti-tumor role, and has a good market application prospect.

The invention relates to the technical field of small molecule bonding drugs, in particular to an activated type methylene blue bonding drug which comprises an adriamycin-methylene blue bonding drug DOX-MB and a 1-methyl-tryptophan-methylene blue bonding drug MT-MB. Two bonding drugs DOX-MB or MT-MB based on methylene blue are designed and synthesized, MT or DOX is bonded with methylene blue through urea bonds, and the synthesis method is simple and easy to implement; the two bonding drugs DOX-MB or MT-MB and the distearoyl phosphatidyl ethanolamine-polyethylene glycol are assembled in an aqueous solution to form the nano-drug, so that efficient loading of DOX or MT can be realized; the bonding drug DOX-MB or MT-MB has no cytotoxicity, and singlet oxygen generated by methylene blue under near-infrared laser irradiation or ultrasonic conditions can break urea bonds to release a parent drug, so that precise and controllable release and combined treatment of the drug are realized; the fluorescence of methylene blue in the bonding drug DOX-MB or MT-MB is quenched, and the methylene blue fluorescence released by urea bond breakage under near-infrared laser irradiation or ultrasonic conditions is recovered, so that the method can be used for real-time detection of drug release.

The invention relates to the technical field of cosmetics, in particular to a sensitive skin repairing composition and application thereof.The mask liquid is prepared from chamomile oil, tea tree oil, radix gentianae extract, centella asiatica extract, 4-tert-butyl cyclohexanol, butanediol, phosphatidyl ethanolamine and cardiolipin. Phosphatidyl ethanolamine ester is modified, the weight ratio of all the components is adjusted, all the components in the composition are coordinated to play the optimal functions of diminishing inflammation, resisting allergy, easing pain and repairing, exogenous stimulation, nerve stress response and inflammatory response are reduced, meanwhile, the self-protection mechanism is strengthened, the skin barrier is repaired, and the skin repairing effect is achieved. The composition disclosed by the invention is free from preservatives, natural and safe, so that the product is milder and does not generate side effects such as dependence and drug resistance after being used for a long time.